media – Page 374 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Ariceum and UCB link up to take on immune-related diseases

The companies will use proprietary technology to enable the discovery of peptide-radioisotope conjugates Ariceum Therapeutics and UCB have announced a research partnership agreement to establish and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumours and immune-related diseases. An essential part of the collaboration will involve the companies utilising each other’s proprietary technology platforms to enable the discovery of peptide-radioisotope conjugates as treatments for a variety of cancers and immune-related diseases. In addition, Ariceum will gain access to UCB’s experience in order to identify novel synthetic macrocyclic peptides by incorporating its mRNA-display technology platform, ExtremeDiversity. Similarly, UCB will benefit from Ariceum’s expertise in the areas of radiochemistry and labelling technology, thereby enhancing its ability to study how this type of technology could lead to the discovery of differentiated products for immune-related diseases. Indeed, the agreement means that each company will have the opportunity to explore multiple targets. Dhaval ...
- Source: drugdu
- 121
- May 15, 2023
NHS misses targets in England to tackle care backlogs

IMAGE SOURCE,GETTY IMAGES By Nick Triggle Health correspondent Hospitals in England have failed to hit key targets to tackle the backlogs in cancer care and routine treatment. Waiting times show too many patients were still facing long waits at the end of March. The targets were to eliminate 18-month waits for planned care, such as knee and hip replacements, and to bring 62-day cancer waits to pre-pandemic levels. NHS England said huge progress had been made, particularly on routine care. The numbers waiting more than 18 months for treatment peaked in September 2021 at nearly 125,000. By the end of March, just over 10,700 were waiting that long – but NHS England said about 4,000 of them were complex cases or patients who had been offered treatment but had chosen to wait. Half of the people were concentrated in 10 NHS trusts. Overall, there are now a record 7.3 million ...
- Source: drugdu
- 110
- May 15, 2023
WHO declares global emergency over

IMAGE SOURCE,GETTY IMAGES Image caption, Monkeypox is caused by the monkeypox virus, a member of the same family of viruses as smallpox BBC By Michelle Roberts Digital health editor Monkeypox is no longer a global public health emergency, the World Health Organization (WHO) has said, almost a year after the threat was raised. The virus is still around and further waves and outbreaks could continue, but the highest level of alert is over, the WHO added. The global health body’s chief Tedros Adhanom Ghebreyesus called on countries to “remain vigilant”. It can be passed on by close contact with someone who is infected. What is monkeypox? Its official name is Mpox and it is caused by the monkeypox virus, a member of the same family of viruses as smallpox, although it is much less severe. Initial symptoms include fever, headaches, swellings, back pain, aching muscles. Once the fever breaks ...
- Source: drugdu
- 94
- May 15, 2023
ImmunityBio gets manufacturing-related FDA snub on cancer drug, shares crash

ImmunityBio was hit with a complete response letter from the FDA for its bladder cancer prospect, sending the California-based company’s stock into a steep slide Thursday. The company’s stock fell more than 50% in overnight trading after it announced in a Securities and Exchange Commission filing Wednesday that it received a CRL from the agency on its application for its drug Anktiva in combination with a vaccine mainly used against tuberculosis, Bacillus Calmette-Guérin. The treatment is designed for patients with BCG-unresponsive, non-muscle invasive bladder cancer. Shares in the overnight session tumbled to $3.39 from Wednesday’s closing price of $6.22. “The deficiencies relate to the FDA’s pre-license inspection of the company’s third-party contract manufacturing organizations,” ImmunityBio said in the filing. “Satisfactory resolution of the observations noted at the pre-license inspection is required before the [application] may be approved.” ImmunityBio said it has requested a meeting with the FDA to address the agency’s concerns. The ...
- Source: https://seekingalpha.com/news/3969942-immunitybio-stock-crashes-after-fda-snub-cancer-therapy
- 119
- May 14, 2023
Cytiva and Pall Life Sciences complete integration

Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. With nearly 16 000 associates in 40 countries, and more than 300 years’ heritage of trusted expertise, the new Cytiva supports customers in solving major biotechnology challenges and plays a critical role in advancing and accelerating therapeutics for the benefit of patients everywhere. In January 2023, the life sciences business of Pall separated from Pall Corporation. Pall’s biotech portfolio is now a product family in Cytiva’s bioprocess business. The Pall medical portfolio will remain a market brand and part of Cytiva. Pall Corporation continues to operate as a Danaher operating company serving customers across a wide range of industrial applications. “The biotechnology industry is at the start of a new era. New modalities are emerging, there is greater emphasis on local manufacturing, and we are accelerating ...
- Source: https://www.news-medical.net/news/20230512/Cytiva-and-Pall-Life-Sciences-complete-integration-to-create-a-global-innovation-and-solutions-leader-in-biotechnology.aspx
- 202
- May 14, 2023
Despite rough quarter, Bayer’s duo of Nubeqa and Kerendia continue to excel

As Bayer presented its first-quarter earnings, much of the focus centered on the company’s struggling agricultural sector, which has been hindered by the poor performance of its glyphosate-based weedkillers. Somewhat under the radar is Bayer’s pharma business, which could use a boost as well. On the company’s list of best-selling medicines, seven of the top 10 posted a sales decline from the first quarter of last year. That list doesn’t include the aging eye treatment Eylea, which was up 2% on the quarter. Still, the drug posted a sequential (PDF) sales decline of 4% from the fourth quarter of last year. It all adds up to lots of pressure to perform for Bayer’s most promising new treatments—prostate cancer drug Nubeqa and kidney disease therapy Kerendia. Bayer’s small dose of good news on Thursday is that both are progressing nicely. The company has projected the drugs will generate 3 billion euros ($3.2 billion) each at peak. During the ...
- Source: https://www.fiercepharma.com/pharma/rough-quarter-bayers-duo-nubeqa-kerendia-continue-excel
- 121
- May 14, 2023
Sobi to acquire CTI BioPharma for approximately $1.7bn

Swedish Orphan Biovitrum (Sobi) has said it will acquire CTI BioPharma for approximately $1.7bn, marking a notable expansion to the Swedish drugmaker’s rare haematology pipeline. The deal will grant Sobi access to the US biopharma’s recently-approved Vonjo (pacritinib), a novel oral kinase inhibitor for patients with myelofibrosis and severe thrombocytopenia. The drug was granted accelerated approval by the US Food and Drug Administration (FDA) in February last year to treat adults with intermediate or high-risk primary or secondary myelofibrosis with low platelet counts. This was based on positive results from a phase 3 trial of Vonjo in patients with myelofibrosis. Results showed that 29% of patients receiving Vonjo had a reduction in spleen volume of at least 35% compared to 3% of patients receiving best available therapy. Sobi said Vonjo will be ‘highly complementary’ to Doptelet (avatrombopag), its oral thrombopoietin receptor agonist which also addresses rare haematological platelet disorders. Guido ...
- Source: https://www.pmlive.com/pharma_news/sobi_to_acquire_cti_biopharma_for_approximately_$1.7bn_1491454
- 122
- May 14, 2023
Amylyx’s ALS drug again surpasses Wall Street expectations

Amylyx Pharmaceuticals has again impressed Wall Street, disclosing Thursday a new earnings report in which product revenue was significantly higher than many analyst forecasts. The Cambridge, Massachusetts-based biotechnology company said product revenue from January through the end of March totaled $71.4 million, up from the nearly $22 million generated during the final three months of last year. Amylyx has one product, an ALS medicine sold as Relyvrio in the U.S. and Albrioza in Canada. The company is now profitable less than a year into the drug’s launch, having posted nearly $1.6 million in net income during its latest quarter. In March, Amylyx executives told investors Relyvrio’s launch was going better than expected. They estimated that more than 1,300 U.S. patients with ALS, or amyotrophic lateral sclerosis, were taking the drug at the end of last year, and that the company was on pace to double this ...
- Source: https://www.biopharmadive.com/news/amylyx-als-relyvrio-sales-first-quarter/650139/
- 113
- May 14, 2023
A machine-learning approach for the early diagnosis of Parkinson’s disease

By Dr. Priyom Bose, Ph.D.May 11 2023Reviewed by Benedette Cuffari, M.Sc. Among all neurological diseases, the incidence of Parkinson’s disease (PD) has increased significantly. PD is typically diagnosed on the basis of motor nerve symptoms, such as resting tremors, rigidity, and bradykinesia. However, the detection of non-motor symptoms, such as constipation, apathy, loss of smell, and sleep disorders, could help in the early diagnosis of PD by several years to decades. In a recent ACS Central Science study, scientists from the University of New South Wales (UNSW) discuss a machine learning (ML)-based tool that can detect PD years before the first onset of symptoms. Study: Interpretable Machine Learning on Metabolomics Data Reveals Biomarkers for Parkinson’s Disease. Image Credit: SomYuZu / Shutterstock.com Background At present, the overall diagnostic accuracy for PD based on motor symptoms is 80%. This accuracy could be increased if PD was diagnosed based on biomarkers rather than primarily depending on physical symptoms. Several ...
- Source: https://www.news-medical.net/news/20230511/A-machine-learning-approach-for-the-early-diagnosis-of-Parkinsons-disease.aspx
- 108
- May 14, 2023
Maximizing the Value of AI in Cancer Care

Real-time patient experiences is the missing element to most electronic health records, artificial intelligence, and machine learning models today. Anish Patankar, SVP, GM, Oncology Informatics Software, Elekta Cancer treatment has come a long way in recent years and is now evolving more rapidly through the integration of artificial intelligence (AI) tools, such as machine learning (ML). Currently, health data exists in many forms, including electronic health records (EHR), diagnostic images, genomic and molecular data, pharmacological data, and patient-reported data. The creation of state-of-the-art cancer treatments can be enhanced by the ways clinicians leverage data to optimize care, and there’s no better way to achieve this than through the use of AI. Completing the picture There is a missing element to most EHR, AI, and ML models today – real-time patient-reported outcomes. This type of data refers to information regarding patients’ experiences with their medical conditions, treatments, and healthcare providers, ...
- Source: drugdu
- 147
- May 14, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.